Imagine your doctor handing you a prescription…
for another 70 years of life.
Sounds like science fiction.
But that's exactly what one man in Boston is building.
His name is Alex Zhavoronkov.
His company is InSilico Medicine.
And his pitch is unforgettable:
"My job is to make you live much, much longer."
Zhavoronkov isn't chasing a better painkiller.
He's chasing 150-year human lifespans.
He calls it the Olympus of drugs — a God-tier longevity treatment, designed end-to-end by AI.
And here's the thing… he's already done the impossible once.
InSilico became the first company in history to take a fully generative-AI-discovered drug into human clinical trials — an idiopathic pulmonary fibrosis treatment now called Rentosertib.
Time from idea to Phase 1? Under 30 months. Big Pharma normally takes years longer.
The industry has noticed. Loudly.
The Lilly upfront payment alone is expected to double InSilico's revenue this year.
Profitability? Zhavoronkov says it's coming within 3 years.
Cash runway? A comfy 5 to 6 years. No rush to raise.
InSilico is headquartered in Boston.
But its real war room is in China.
Why?
Because Chinese biotech firms move at warp speed.
"In some areas, the West cannot compete anymore," he says.
His strategy has a name: "China for China."
Build novel drugs inside the world's biggest emerging market — before local rivals can copy the playbook.
Here's where it gets spicy.
The AI evangelist… is sounding the AI alarm.
"There is clearly a huge bubble. When it bursts, it could be bigger than 2008."
His line of the year:
👉 "It's like a Formula One team made out of horse farmers."
Translation — too many AI startups with billion-dollar valuations and zero domain expertise.
For decades, longevity research lived in the world of supplements, smoothies and Silicon Valley billionaires injecting their sons' blood.
InSilico wants to drag it into the world of regulated, AI-designed pharmaceuticals.
If it works, life expectancy stops being a number on an actuarial chart.
It becomes a product.
And the company that ships it first… won't just be the next trillion-dollar pharma.
It'll be the one that quietly rewrote what it means to be human.
That's all for now!
